Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 956

Sort by

Sort Order Select

Journal Articles

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Blood (2021) 137 (23): 3212–3217.

https://doi.org/10.1182/blood.2021010867

Published: 2021

Includes: Supplemental data

Journal Articles

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

Vandana Chaturvedi, Rebecca A. Marsh, Adi Zoref-Lorenz, Erika Owsley, Vijaya Chaturvedi, Trung C. Nguyen, Jordana R. Goldman, Michael M. Henry, Jay N. Greenberg, Stephan Ladisch, Michelle L. Hermiston, Michael Jeng, Ahmed Naqvi, Carl E. Allen, Hector R. Wong, Michael B. Jordan

Blood (2021) 137 (17): 2337–2346.

https://doi.org/10.1182/blood.2020009499

Published: 2021

Includes: Supplemental data

Journal Articles

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Kodandaram Pillarisetti, Suzanne Edavettal, Mark Mendonça, Yingzhe Li, Mark Tornetta, Alexander Babich, Nate Majewski, Matt Husovsky, Dara Reeves, Eileen Walsh, Diana Chin, Leopoldo Luistro, Jocelin Joseph, Gerald Chu, Kathryn Packman, Shoba Shetty, Yusri Elsayed, Ricardo Attar, François Gaudet

Blood (2020) 135 (15): 1232–1243.

https://doi.org/10.1182/blood.2019003342

Published: 2020

Includes: Supplemental data

Journal Articles

Supercharging your CAR

Sneha Ramakrishna, Kara L. Davis

Blood (2020) 135 (9): 593–594.

https://doi.org/10.1182/blood.2019004469

Published: 2020

Journal Articles

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Blood (2020) 135 (1): 28–40.

https://doi.org/10.1182/blood.2019000032

Published: 2020

Includes: Supplemental data

Journal Articles

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Pieternella Lugtenburg, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, MDFRCP, Kim Linton, PhD, Simon Rule, Roberto S Oliveri, MD PhD, Dena DeMarco, Ida H Hiemstra, PhD, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings, MD PhD

Blood (2019) 134 (Supplement_1): 758.

https://doi.org/10.1182/blood-2019-121460

Published: 2019

Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2019) 134 (Supplement_1): 762.

https://doi.org/10.1182/blood-2019-122451

Published: 2019

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, MD, Anthony Stein, MD, Roland B. Walter, MD PhD MS, Ravi Bhatia, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, David Ritchie, MD PhD, Veit Bücklein, MD, Pankit Vachhani, MD, Tian Dai, PhD, Antreas Hindoyan, PhD, Suresh Agarwal, PhD, Abraham Anderson, Sophia Khaldoyanidi, MD PhD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 833.

https://doi.org/10.1182/blood-2019-127977

Published: 2019

Journal Articles

Preclinical Validation of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 856.

https://doi.org/10.1182/blood-2019-123328

Published: 2019

Journal Articles

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Jonathan Webster, MD, Richard F. Ambinder, MD, Richard J. Jones, MD, Nina D. Wagner-Johnston, MD, Gabrielle T. Prince, MD, Audra Shedeck, CRNP, Amanda Blackford, MS, Leo Luznik, MD, Ivana Gojo, MD

Blood (2019) 134 (Supplement_1): 778.

https://doi.org/10.1182/blood-2019-128255

Published: 2019

Journal Articles

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Max Jan, MD PhD, Ana Castano, MD, Amanda Walker, BA, Andrew A Guirguis, MD PhD, Jessica A Gasser, PhD, Amanda A Bouffard, Mikolaj Slabicki, PhD, Alexander Tepper, Daniel E Grinshpun, Taeyoon Kyung, PhD, Quinlan Sievers, MD PhD, Michael E Birnbaum, PhD, Marcela V Maus, MD PhD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 866.

https://doi.org/10.1182/blood-2019-124210

Published: 2019

Journal Articles

Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function

Justin C. Boucher, PhD, Gongbo Li, PhD MBBS, Hiroshi Kotani, MD PhD, Maria Cabral, Dylan Morrissey, Sae Bom Lee, Kristen Spitler, Nolan Beatty, Bishwas Shrestha, PhD, Bin Yu, Aslamuzzaman Kazi, Xuefeng Wang, PhD, Said Sebti, PhD, Marco L. Davila, MD PhD

Blood (2019) 134 (Supplement_1): 248.

https://doi.org/10.1182/blood-2019-122954

Published: 2019

Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 1584.

https://doi.org/10.1182/blood-2019-123949

Published: 2019

Journal Articles

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1585.

https://doi.org/10.1182/blood-2019-123933

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Pier Edoardo Rovatti, MD, Laura Zito, MSc, Eleonora Draghi, MSc, Monika Herrmann, PhD, Anetta Marcinek, MSc, Bettina Brauchle, MSc, Cesare Covino, MSc, Mattia Di Bono, MSc, Matteo Giovanni Carrabba, MD, Massimo Bernardi, MD, Karl-Peter Hopfner, PhD, Cristina Toffalori, PhD, Fabio Ciceri, MD, Marion Subklewe, MD, Luca Vago, MD PhD

Blood (2019) 134 (Supplement_1): 513.

https://doi.org/10.1182/blood-2019-126641

Published: 2019

Journal Articles

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Jean-Pierre Delord, MD, Nuria Kotecki, MD, Aurelien Marabelle, MD PhD, Armelle Vinceneux, MD, Iphigenie Korakis, MD, Christiane Jungels, MD, Stéphane Champiat, MD, Richard D. Huhn, MD, Nicolas Poirier, PhD, Dominique Costantini, MD, Bérangère Vasseur, MD, Philippe A. Cassier, MD

Blood (2019) 134 (Supplement_1): 1040.

https://doi.org/10.1182/blood-2019-124876

Published: 2019

Journal Articles

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Meixiao Long, MD, Erich Williams, Clara Berard, Carolyn Cheney, BS, Eileen Hu, BS, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1049.

https://doi.org/10.1182/blood-2019-125417

Published: 2019

Journal Articles

15-PGDH Inhibition Mitigates Aplastic Anemia Severity

Julianne N. P. Smith, PhD, Folashade Otegbeye, MBBChir,MPH, Alvin Jogasuria, Sanford Markowitz, MD PhD, Amar Desai, PhD

Blood (2019) 134 (Supplement_1): 1220.

https://doi.org/10.1182/blood-2019-131353

Published: 2019

NARROW

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Supercharging your CAR

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody ® -CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Preclinical Validation of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

15-PGDH Inhibition Mitigates Aplastic Anemia Severity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only